Mounting a fightback: Covid-19 vaccine developers reach last leg of trials

As US regulators tighten the scrutiny around approvals, companies have announced their intention to put their trial data in public domain for scientific enquiry to remove any doubt about safety and efficacy.
Source: The Economic Times - Category: Consumer Health News Source Type: news
More News: COVID-19 | Health | Vaccines